Author: Nienke Groenendijk

  • Visit to European Parliament

    This week, three team members of the Alpha1 MZ Foundation will visit the European Parliament. They have been invited by ELPA, the European Liver Patients’ Association. The mission of the Foundation is to raise awareness of the significant impact of Alpha-1 Antitrypsin Deficiency (MZ genotype) on European GDP and public health.

    Click here to read our mission statement.

    We will keep you posted!

  • Standing Together This Thanksgiving

    Your Support Can Change the Story for Millions

    Dear friends,

    As we move into this season of Thanksgiving, a time for family, connection, gratitude, and taking care of one another, we are reminded of how important it is to support those who may be quietly struggling, without answers, and often without recognition.

    Many of you know that our work with the Alpha1 MZ Foundation has become a personal mission for us. The more we learn, the clearer it becomes that millions of people with the Alpha-1 MZ genotype are living with unexplained health challenges, and most have never been told why.

    This year, we discovered and confirmed essential insights, including that:

    • ~10% of all liver transplants are MZs.
    • The MZ liver decompensates twice as fast
    • Gallstones and bile duct issues are ~50% more common
    • The MZ genotype is the #1 genetic cause of ICP (3× higher risk during pregnancy)
    • Reticulocytes are reduced by 31%, affecting red blood cell function
    • COPD and bronchitis risk increases by ~40%
    • Hormonal dysregulation
    • Rheumatoid arthritis is 3× more likely

    And yet, most of these people are still told they are not sick and are dismissed, without the proper treatment.

    That is why we are working hard to change this!!

    This Thanksgiving, we are asking for your support so we can continue our work in four key areas:

    1. Awareness & Recognition
      Educating governments, medical organizations, and healthcare organizations to acknowledge the real impact on Alpha1 MZ patients. (Including SZ)
    2. Global Expansion
      Building communities and support networks so patients around the world are no longer alone, including bridging the language barriers.
    3. Education for Patients and Families
      Giving patients and families the knowledge and confidence to advocate for better care, through our educational newsletters and events, highlighted by the highly successful webinar we presented in October.
    4. Fundamental Research
      Including biobanks, biomarkers, and especially Intrahepatic Cholestasis of Pregnancy, where the lives of mothers and babies are directly and seriously affected.

    There are 35 million MZ individuals worldwide, and far too many are suffering without understanding the cause, some with liver disease, some with lung issues, some with pregnancy complications, some with autoimmune problems, and many simply feeling unwell without a proper diagnosis and answers.

    This Thanksgiving, we have an opportunity to change that, together.

    If you feel moved to support our mission, your contribution, large or small, will help us reach more patients with early detection, engage more doctors, accelerate research, education, and webinars, reduce misdiagnosis, prevent suffering, and give patients a voice

    We also kindly ask you to share this message with family and friends when appropriate. Every person who learns about this makes our community stronger, raises awareness, and brings us closer to proper recognition and care for the MZ population.

    From the bottom of our hearts, thank you for caring, and thank you for helping us build a world where MZ patients are finally understood, diagnosed, and supported.

    Wishing you and your family a warm, healthy, and meaningful Thanksgiving,

    The Alpha1 MZ Foundation Global Team
    (Reinoud, Nienke, Margaret, Jorieke, Laura, Natalia, Fiona and Frans)

    👉 Donate today on our website and help move us one step closer to a cure.

    Your support truly makes a difference.

  • Videos of our webinar

    Our webinar that took place in October 2025 was a great success and fortunately we have recorded it.

    We have split the video in separate parts for each speaker, so they can be easily located and watched on our YouTube-channel.

    Click here for the first video, with an introduction by our founder, Frans Frielink, and a presentation by professor Gerry McElvany, called “Delineating the risk of lung disease in MZ alpha-1 antitrypsin deficiency”.

    Click here for the second video, in which Frans Frielink shares his insights on Alpha-1 MZ liver-related morbidities and mechanics.

    The other three video’s will be posted soon, so check out our YouTube-channel or this website regularly!

  • Alpha1 MZ Foundation on Substack

    Until now, we’ve sent our weekly newsletters via an e-mail service connected to this website. Over the past few months, we’ve welcomed so many new subscribers that this option is no longer feasible. We’ve reached the milestone of 500 subscribers, which means we had to look for other possibilities to distribute our newsletters.

    We all thought Substack would be an excellent choice to keep you updated on the latest developments for the Alpha MZ population.

    From now on, you’ll receive our newsletter directly in your inbox. You can also log in to our Substack website to read the full archives and other posts as they’re published.

    So feel free to subscribe to our publications and tell your friends, family and fellow Alpha’s about us.